We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Data presented at the American Academy of Allergy Asthma and Immunology 61st
Annual Meeting show that once-daily treatment with the investigational therapy
Alvesco is associated with a low incidence of local oropharyngeal side effects
(thrush, hoarseness and sore throat), and is well-tolerated in pediatric patients
with mild-to-severe asthma.
Protein Design Labs (PDL) has discussed with the FDA the future development
pathway for PDL's Nuvion humanized anti-CD3 antibody being developed for the
treatment of intravenous steroid-refractory ulcerative colitis.
Nymox Pharmaceutical's lead drug candidate NX-1207 for the treatment of benign
prostatic hyperplasia (BPH) shows good promise as a potential first-line treatment
for BPH.
Health Canada has given regulatory clearance for the Adherex Technologies' Phase
II clinical trial application for ADH-1, the company's lead antitumor biotechnology
compound, also known as Exherin.
The Gynecologic Oncology Group (GOG) has initiated a Phase III clinical trial
examining the ability of Xyotax to maintain remission and prolong the survival
of ovarian cancer patients.
Join FDAnews Wednesday, March 30, for an audioconference on "Pharma
& the HIPAA Security: 10 Critical Changes to Make Before the April 20 Deadline."
Make sure your organization has implemented all the new administrative, physical
and technical safeguards required to meet the deadline for the HIPAA security
rule.
Lorus Therapeutics has announced that its wholly owned subsidiary GeneSense
Technologies has received notice from the European Patent Office of its intention
to grant the GeneSense application for a patent of its novel antisense drug
GTI-2040.